Fate Therapeutics Inc. (FATE)

The total asset value of Fate Therapeutics Inc. (FATE) stood at $ 585 Mln as on 30-Sep-23

The share price of Fate Therapeutics Inc. (FATE) is $2.40 (NASDAQ) as of 06-Dec-2023 16:00 EST. Fate Therapeutics Inc. (FATE) has given a return of -65.95% in the last 3 years.

Fate Therapeutics Inc. (FATE) has a market capitalisation of $ 233 Mln as on 24-Nov-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Fate Therapeutics Inc. (FATE) is 2.88 times as on 24-Nov-2023, a 0.13% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Fate Therapeutics Inc. (FATE) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Fate Therapeutics Inc. (FATE) and enter the required number of quantities and click on buy to purchase the shares of Fate Therapeutics Inc. (FATE).

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

The CEO & director of Mr. J. Scott Wolchko. is Fate Therapeutics Inc. (FATE), and CFO & Sr. VP is Mr. Edward J. Dulac III.

The promoters of Fate Therapeutics Inc. (FATE) have pledged 0% of the total equity as on Jun-23.

Some of the close peers are:

No, TTM profit after tax of Fate Therapeutics Inc. (FATE) was $-19 Mln.